Newscast – Page 92 – media

Pfizer announces second year of UK-based startup innovation competition

Pfizer announced today that it is receiving applications for its Pfizer Healthcare Hub: London competitive grant. This is the second time that Pfizer has held the startup-focused program, which representatives from biopharmaceutical company said had a strong inaugural year in 2017.
- Source: MobiHealthNews
- 689
- April 9, 2018
Company Insights healthcare Pfizer
Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio

Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
- Source: finance.yahoo
- 526
- April 8, 2018
CAR-T therapy immuno-oncology Market Views
Hydrogel delivery enables long-lasting, ‘flare-responsive’ arthritis treatment

Although inflammatory arthritis can be treated systemically, drugs are often injected directly into affected areas, particularly when the disease affects just one or a few joints. Problem is, injectable drugs are usually cleared quickly from the joint, limiting their effectiveness. A new delivery system could improve the efficacy and durability of arthritis treatments, as well as cut down on nasty side effects caused by systemic therapy.
- Source: fiercebiotech
- 501
- April 8, 2018
arthritis Researches
Macrolide Pharmaceuticals Appoints New President and CEO Raises $20 Million in Investor Financing by Allyson English

Macrolide Pharmaceuticals, a next-generation antibiotics company developing macrolides that are first-in-class with Gram-negative activity for a broad range of multi-drug resistant bacterial infections, announced that Mahesh Karande has joined the company as President and CEO. The company is also pleased to announce the completion of a $20 million financing led by current investors Advent Life Sciences, Gurnet Point Capital, Novartis Venture Fund, Roche Venture Fund and SR One.
- Source: macrolide
- 470
- April 8, 2018
macrolide antibiotics Market Views
Quick-acting ‘injectable bandage’ developed from seaweed

Researchers have developed an "injectable bandage" that quickly stops bleeding and allows wounds to heal faster than traditional dressings. Biomedical engineers at Texas A&M University in College Stations have invented the "injectable bandage," which is composed of a seaweed-derived gelling agent and two-dimensional clay nanoparticles.
- Source: upi
- 530
- April 8, 2018
injectable bandage Researches
Rumours Allergan is looking to offload $5bn women’s health unit

According to a piece by Bloomberg, Allergan is looking at options to divest its women’s health unit in a move that could potentially reap about $5 billion.
- Source: pharmafile
- 625
- April 6, 2018
Allergan biosimilar Company Insight
Overriding EHR Alerts May Up Adverse Drug Events

Such alerts remind clinicians about everything from a patient's drug allergies, to possible drug interactions, to dosing guidelines, to lab testing guidance. Clinicians can either follow the alerts' recommendations, override them, or ignore them.
- Source: MedPageToday
- 691
- April 6, 2018
digital health EHR Researches
Singapore’s Aslan stalks $86M IPO to fund cancer pipeline

Aslan wants to list on the U.S. exchange under the ASLN symbol.
- Source: fiercebiotech
- 554
- April 5, 2018
Aslan Market Views varlitinib
Apple’s PHR health system partnerships up threefold

Health Records is based on the interoperability standard FHIR and collects encrypted medical data on allergies, immunizations, lab results, medications, procedures, vital signs and conditions. Users will receive notifications when their data are updated.
- Source: HealthCareDive
- 950
- April 5, 2018
Company Insights mHealth PHR
Using CRISPR to introduce beneficial but rare gene mutations in sickle cell

People who suffer from the inherited disease sickle cell disease have defects in their hemoglobin, the blood molecule that transports vital oxygen throughout the body. But a small percentage of patients with the disease have beneficial gene mutations that lessen their symptoms. The mutations switch on a gene that produces fetal hemoglobin—a type of the blood molecule that the body normally stops producing in infancy. The lifelong production of fetal hemoglobin helps shield those sickle cell patients from the worst effects of the disease.
- Source: fiercebiotech
- 485
- April 5, 2018
Researches sickle cell disease

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.